UBI
$4M4mo
Universal Biosensors
Diagnostics
Point-of-use biosensor company with products across wine analysis (Sentia), coagulation testing (Xprecia Prime), and an early-stage oncology biomarker pipeline.
Cash data from Mar 2025 4C(12mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$4.9M
Mar 2025 4C
Runway
4moCRITICAL
Based on Mar 2025 4C
Market Cap
$4M
Burn Rate
$3.7M/qtr
Mar 2025 4C
Shares Outstanding
298M
Pipeline Assets
4
3M Price
UBI.ASX$0.014+0.0% 3M
Low $0.014High $0.014
Pipeline Assets (4)
Tn Antigen BiomarkerOncology screening
DiscoveryAquascoutWater quality testing
PreclinicalSentia Wine AnalyserWine quality testing
ApprovedXprecia PrimePT-INR coagulation testing
ApprovedDiscovery
Preclinical
Ph 1
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
50 competitor trialsPhase 2+ · Non-ASX
Oncology Screening50 active trials
12 Ph47 Ph33 Ph2/324 Ph24 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
Aquascout commercial launch
UpcomingExpectedarrow_upwardHigh30 June 2026
Tn Antigen cancer biomarker feasibility data
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Aquascout commercial launch | commercial milestone | Expected | arrow_upwardHigh | 30 June 2026 |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(1)
No active trials